Evidence map›Paper›PMID 40451640›Full record

SynthesisBest practice & research. Clinical gastroenterology2025

Cost effectiveness analysis of Barrett's esophagus screening: A systematic review.

Caroline L Matchett, Mert Sahinkoc, Jagpreet Chhatwal, John B Kisiel, Prasad G Iyer

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Best practice & research. Clinical gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Biomarker Use in Barrett's Esophagus Surveillance.The American journal of gastroenterology · 2026
    Review
  2. Screening for Barrett's esophagus and esophageal adenocarcinoma: recent advances and next steps.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2026
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Caroline L MatchettDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Mert SahinkocInstitute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jagpreet ChhatwalInstitute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
John B KisielDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Prasad G IyerDivision of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ, USA. Electronic address: iyer.prasad@mayo.edu.

Funding

Minimally Invasive Molecular Approaches for the Detection of Barrett’s Esophagus and Esophageal AdenocarcinomaR01CA241164 · NCI · MAYO CLINIC ROCHESTER · PI Jagpreet Chhatwal, Prasad G. Iyer · 2019 to 2026
$3.9M
NCI NIH HHS R01 CA241164
6 · The paper itself

Abstract

Barrett's esophagus screening is critical for early detection of esophageal adenocarcinoma, but optimal strategies remain debated. This systematic review analyzed thirteen studies evaluating screening cost-effectiveness through September 2024. Both traditional endoscopic and emerging non-endoscopic methods were cost-effective compared to no screening, with incremental cost-effectiveness ratios below standard willingness-to-pay thresholds. Non-endoscopic approaches, particularly swallowed cell collection devices with biomarkers, demonstrated superior cost-effectiveness versus standard endoscopy. Cost-effectiveness improved in populations with higher disease prevalence. Current evidence supports implementing screening programs, especially using non-endoscopic methods in high-risk populations. Future research should focus on validating risk stratification tools to further optimize screening approaches.

Indexed as

AdenocarcinomaBarrett EsophagusCost-Benefit AnalysisEarly Detection of CancerEsophageal NeoplasmsEsophagoscopyMass ScreeningCost-Effectiveness AnalysisHumansBarrett esophagusCost-benefit analysisEarly detection of cancerHealth economicsMass screeningSystematic review

Identifiers

PMID40451640
PMCPMC12127660

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.